白蛋白批次与B19细小病毒DNA。
Albumin batches and B19 parvovirus DNA.
作者信息
Lefrère J J, Mariotti M, De la Croix I, Lerable J, Thauvin M, Burnouf T, Folléa G
机构信息
Institut National de Transfusion Sanguine, Hôpital Saint-Antoine, Paris, France.
出版信息
Transfusion. 1995 May;35(5):389-91. doi: 10.1046/j.1537-2995.1995.35595259148.x.
BACKGROUND
B19 parvovirus (B19) may be transmitted iatrogenically by blood, and its prevalence in blood donations is estimated at 1 in 3,300 to 1 in 50,000. As a large number of blood donations make up the plasma pools used to produce plasma derivatives, even a virus as rare as B19 in a population of blood donors may result in the frequent contamination of plasma batches. The percentage of albumin batches containing B19 DNA has never been determined.
STUDY DESIGN AND METHODS
The presence of B19 DNA was investigated by a polymerase chain reaction assay (with a primer pair in the VP1 region) in a total of 12 and 17 batches of 4- and 20-percent albumin, respectively, from two different manufacturers.
RESULTS
No B19 DNA was detected in the batches tested.
CONCLUSION
The current fractionation process used to obtain these albumin preparations is seen to allow the efficient degradation and/or elimination of B19.
背景
B19细小病毒（B19）可能通过血液医源性传播，其在献血中的流行率估计为3300分之一至50000分之一。由于大量献血构成了用于生产血浆衍生物的血浆库，即使是献血人群中像B19这样罕见的病毒，也可能导致血浆批次频繁污染。含有B19 DNA的白蛋白批次的百分比从未确定过。
研究设计与方法
通过聚合酶链反应检测法（使用VP1区域的一对引物）分别对来自两个不同制造商的总共12批4%白蛋白和17批20%白蛋白进行B19 DNA检测。
结果
在所检测的批次中未检测到B19 DNA。
结论
目前用于获得这些白蛋白制剂的分馏过程被认为能够有效降解和/或消除B19。
Zotero 插件